Phase 2 Dose-Ranging Trial of VGT-309 for Molecular Imaging of Cancer during Pulmonary Resection
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Cardio-Thoracic Surgery"
DOI: 10.1093/ejcts/ezaf314
Abstract: Abstract Objectives VGT-309 (abenacianine) is being evaluated as an intraoperative molecular imaging (IMI) agent. This phase 2, open-label, dose-ranging study evaluated efficacy and safety in participants undergoing surgical resection of suspicious or proven cancer in… read more here.
Keywords: cancer; dose ranging; dosed hours; vgt 309 ... See more keywords